Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China
February 05 2024 - 7:51AM
Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY)
(“Clearmind” or the "company"), a biotech company focused on
discovery and development of novel psychedelic-derived therapeutics
to solve major under-treated health problems, announced today that
it has been granted divisional patent approval by the China
National Intellectual Property Administration.
The granting of this latest patent establishes both the
company's patent protection around its flagship molecule as well as
its extensive IP protection in the psychedelic space. Clearmind’s
IP portfolio consists of fifteen utility patent families, including
patents and applications having method of use and composition of
matter claims which includes 24 pending patent applications and 27
granted patents in major jurisdictions such as the US, Europe,
China, and India.
"We are proud to receive once again recognition of our
innovative treatment for binge behaviors. This approval is a major
milestone and significantly expands our IP protection as a leader
in psychedelic-derived therapeutics,” said Clearmind’s Chief
Executive Officer, Dr. Adi Zuloff-Shani. “In various pre-clinical
studies, carried out during the past 2 years, MEAI has demonstrated
its ability to regulate binge behaviors, addiction and other mental
health disorders. We believe these strong results demonstrate the
significant potential of the MEAI molecule for various
indications.”
MEAI is a new psychoactive molecule that reduces desire to
consume alcoholic beverages and exerts a slight euphoric,
alcohol-like experience with potential to change the lives of
millions who struggle to drink in moderation. Clearmind’s
MEAI-based flagship treatment focuses on Alcohol Use Disorder,
which is incredibly common. It varies from mild to excessive and is
characterized by a person’s inability to restrict their alcohol
consumption, despite negative social, occupational, or health
consequences. Clearmind’s MEAI may also be used to treat binge
drinking, which can be a deadly addiction for some.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company
focused on the discovery and development of novel
psychedelic-derived therapeutics to solve widespread and
underserved health problems, including alcohol use disorder. Its
primary objective is to research and develop psychedelic-based
compounds and attempt to commercialize them as regulated medicines,
foods or supplements.
The Company’s intellectual portfolio currently consists of
fifteen patent families. The Company intends to seek additional
patents for its compounds whenever warranted and will remain
opportunistic regarding the acquisition of additional intellectual
property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq and the
Canadian Securities Exchange under the symbol "CMND" and the
Frankfurt Stock Exchange under the symbol “CWY.”
For further information
visit: https://www.clearmindmedicine.com or contact:
Investor Relationsinvest@clearmindmedicine.comTelephone: (604)
260-1566US: CMND@crescendo-ir.com
General
InquiriesInfo@Clearmindmedicine.comwww.Clearmindmedicine.com
Forward-Looking
Statements:
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act and
other securities laws. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates” and similar
expressions or variations of such words are intended to identify
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses its position as a
leader in psychedelic-derived therapeutics and the significant
potential of the MEAI molecule for various indications. In
addition, the Company cannot assure that any patent will issue as a
result of a pending patent application or, if issued, whether it
will issue in a form that will be advantageous to the Company.
Forward-looking statements are not historical facts, and are based
upon management’s current expectations, beliefs and projections,
many of which, by their nature, are inherently uncertain. Such
expectations, beliefs and projections are expressed in good faith.
However, there can be no assurance that management’s expectations,
beliefs and projections will be achieved, and actual results may
differ materially from what is expressed in or indicated by the
forward-looking statements. Forward-looking statements are subject
to risks and uncertainties that could cause actual performance or
results to differ materially from those expressed in the
forward-looking statements. For a more detailed description of the
risks and uncertainties affecting the Company, reference is made to
the Company’s reports filed from time to time with the Securities
and Exchange Commission (“SEC”), including, but not limited to, the
risks detailed in the Company’s annual report on Form 20-F filed
with the SEC on January 29, 2024. Forward-looking statements speak
only as of the date the statements are made. The Company assumes no
obligation to update forward-looking statements to reflect actual
results, subsequent events or circumstances, changes in assumptions
or changes in other factors affecting forward-looking information
except to the extent required by applicable securities laws. If the
Company does update one or more forward-looking statements, no
inference should be drawn that the Company will make additional
updates with respect thereto or with respect to other
forward-looking statements. References and links to websites have
been provided as a convenience, and the information contained on
such websites is not incorporated by reference into this press
release. Clearmind is not responsible for the contents of
third-party websites.
Clearmind Medicine (NASDAQ:CMND)
Historical Stock Chart
From Aug 2024 to Sep 2024
Clearmind Medicine (NASDAQ:CMND)
Historical Stock Chart
From Sep 2023 to Sep 2024